Equity · Healthcare
IMRX
NASDAQImmuneering (IMRX)
This price chart is drawn by TradingView, from their own data, in an embed loaded from their servers.
- Market cap
- 299.5M USD
- EPS, diluted, year to Dec 2025
- −1.27 USD
- 52-week range
- 3 USD – 13 USD
- Avg volume
- 255.9K
as of Jul 17, 2026
Have Immuneering (IMRX) insiders bought or sold shares recently?
In the 90 days to 22 Nov 2026, Immuneering insiders reported 1 open-market purchase and no sales (SEC Form 4).
Form 4, 90 days to 22 Nov 2026, newest reported trade 13 Nov 2026
| Reported | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 13 Nov 2026 | Gengos AndrewChief Financial Officer | Buy | 25,000 | 90K USD |
Which funds hold Immuneering (IMRX)?
7 of the 45 institutional funds we track reported a Immuneering position for the quarter ended 30 Sep 2026 — a combined 4.7M USD; the latest of those filings landed 16 Nov 2026.
| Fund | Position | Shares | Value | Shares q/q |
|---|---|---|---|---|
| Marshall Wace | Held (±25%) | 734,366 | 3.0M USD | +0.3% |
| Fisher Asset Management | Added | 115,954 | 475K USD | +31.3% |
| Citadel Advisors | Trimmed | 89,895 | 368K USD | −76.7% |
| Two Sigma Investments | Trimmed | 68,545 | 281K USD | −76.2% |
| D. E. Shaw & Co. | Trimmed | 67,920 | 278K USD | −66.7% |
| Millennium Management | Trimmed | 43,712 | 179K USD | −86.8% |
| AQR Capital Management | New position | 23,460 | 96K USD |
What has been filed or recorded for Immuneering (IMRX)?
The filings we hold for Immuneering, newest first: 9 fails-to-deliver days, 6 quarterly earnings reports, 2 annual reports and 4 reported financial figures, the latest dated 30 Oct 2026. No next earnings date is announced in SEC filings yet.
| And | ||||
|---|---|---|---|---|
| 30 Oct 2026 | Fails to deliver | Shares failed to deliver | 5,041 shares | 20K USD notional · 0.008% of shares out |
| 22 Oct 2026 | Fails to deliver | Shares failed to deliver | 2,188 shares | 8K USD notional · 0.003% of shares out |
| 21 Oct 2026 | Fails to deliver | Shares failed to deliver | 1,748 shares | 7K USD notional · 0.003% of shares out |
| 20 Oct 2026 | Fails to deliver | Shares failed to deliver | 10 shares | 37 USD notional · <0.001% of shares out |
| 16 Oct 2026 | Fails to deliver | Shares failed to deliver | 14,833 shares | 54K USD notional · 0.023% of shares out |
| 15 Oct 2026 | Fails to deliver | Shares failed to deliver | 6,429 shares | 22K USD notional · 0.010% of shares out |
| 09 Oct 2026 | Fails to deliver | Shares failed to deliver | 248,059 shares | 928K USD notional · 0.383% of shares out |
| 08 Oct 2026 | Fails to deliver | Shares failed to deliver | 818 shares | 3K USD notional · 0.001% of shares out |
| 07 Oct 2026 | Fails to deliver | Shares failed to deliver | 36,955 shares | 142K USD notional · 0.057% of shares out |
| 30 Sep 2026 | Quarterly earnings | Q3 2026 reported | EPS −0.37 USD | |
| 30 Sep 2026 | Financials | Total assets | 182.6M USD | at period end |
| 30 Sep 2026 | Financials | Total equity | 168.7M USD | at period end |
| 30 Jun 2026 | Quarterly earnings | Q2 2026 reported | EPS −0.27 USD | |
| 31 Mar 2026 | Quarterly earnings | Q1 2026 reported | EPS −0.21 USD | |
| 31 Dec 2025 | Annual report | FY 2025 reported | EPS −1.27 USD | |
| 31 Dec 2025 | Financials | Net income | −56.0M USD | fiscal year |
| 31 Dec 2025 | Financials | Diluted EPS | −1.27 USD | fiscal year |
| 30 Sep 2025 | Quarterly earnings | Q3 2025 reported | EPS −0.38 USD | |
| 30 Jun 2025 | Quarterly earnings | Q2 2025 reported | EPS −0.40 USD | |
| 31 Mar 2025 | Quarterly earnings | Q1 2025 reported | EPS −0.42 USD | |
| 31 Dec 2024 | Annual report | FY 2024 reported | EPS −2.04 USD |
What do people ask about Immuneering (IMRX)?
What is Immuneering’s market cap?299.5M
Immuneering is worth 299.5M USD by market value as of 17 Jul 2026, which is the share price times the shares on issue from its SEC filings.
Have Immuneering insiders bought or sold shares recently?1 purchase
In the 90 days to 22 Nov 2026, Immuneering insiders reported 1 open-market purchase and no sales (SEC Form 4). See Insiders
Which funds own Immuneering?7 of 45
7 of the 45 funds we track reported a Immuneering position for the quarter ended 30 Sep 2026, per their SEC Form 13F filings. The largest reported positions were Marshall Wace, Fisher Asset Management and Citadel Advisors. See Funds
When did Immuneering last report earnings?−0.37
Immuneering last reported earnings on 30 Sep 2026 for Q3 2026, with EPS of −0.37 USD; no next date is announced in SEC filings yet. See Filings

Answers are generated from the live figures on this page — Reddit crowd data, SEC filings and open company records — and update as the data does.
References
- Finazonprior-day close, indicative (IEX-derived, not the official close)
- TradingViewthe price chart widget, drawn by TradingView from their own data
- SEC EDGARForm 4 filings (insider transactions)
- SEC EDGAR13F filings
- SECSEC fails-to-deliver (CNS) data
- SEC EDGARXBRL company facts, latest period ended 30 Sep 2026
- SEC EDGARreported earnings figures and scheduled report dates
- SEC EDGARValuation computed from SEC EDGAR filings
- SEC filingAbout text: the company's latest annual report filed with the SEC (Business section), summarised in our own words